ProCE Banner Activity

COSMIC-021 Phase I Study: Cabozantinib Plus Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage
Phase Ib results suggest cabozantinib plus atezolizumab may be active in mCRPC patients with visceral or extrapelvic lymph node metastases.

Released: September 21, 2021

Expiration: September 20, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc